ATE284959T1 - Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung - Google Patents

Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung

Info

Publication number
ATE284959T1
ATE284959T1 AT95925934T AT95925934T ATE284959T1 AT E284959 T1 ATE284959 T1 AT E284959T1 AT 95925934 T AT95925934 T AT 95925934T AT 95925934 T AT95925934 T AT 95925934T AT E284959 T1 ATE284959 T1 AT E284959T1
Authority
AT
Austria
Prior art keywords
binding
mdm2
disruption
therapeutic application
corresponding therapeutic
Prior art date
Application number
AT95925934T
Other languages
English (en)
Inventor
Steven Michael Picksley
David Philip Lane
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/277,660 external-priority patent/US5702908A/en
Application filed by Univ Dundee filed Critical Univ Dundee
Application granted granted Critical
Publication of ATE284959T1 publication Critical patent/ATE284959T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95925934T 1994-07-20 1995-07-20 Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung ATE284959T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/277,660 US5702908A (en) 1994-07-20 1994-07-20 Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
US08/424,957 US5770377A (en) 1994-07-20 1995-04-19 Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
PCT/GB1995/001719 WO1996002642A1 (en) 1994-07-20 1995-07-20 INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF

Publications (1)

Publication Number Publication Date
ATE284959T1 true ATE284959T1 (de) 2005-01-15

Family

ID=26958629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95925934T ATE284959T1 (de) 1994-07-20 1995-07-20 Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung

Country Status (9)

Country Link
US (2) US5770377A (de)
EP (1) EP0773996B1 (de)
JP (2) JP3961015B2 (de)
AT (1) ATE284959T1 (de)
AU (1) AU684194B2 (de)
CA (1) CA2195533A1 (de)
DE (1) DE69533855T2 (de)
NZ (1) NZ289899A (de)
WO (1) WO1996002642A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2738151B1 (fr) * 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa Antagonistes de l'activite oncogenique de la proteine mdm2, et leur utilisation dans le traitement des cancers
AU7127296A (en) * 1995-09-18 1997-04-09 Novartis Ag Assay for identifying inhibitors of the interaction between proteins p53 and dm2
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
GB9620028D0 (en) 1996-09-26 1996-11-13 Ludwig Inst Cancer Res Factors which interact with oncoproteins
GB9708089D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to stabilising substances in cells
GB9708092D0 (en) * 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
US6372490B1 (en) 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
US20040038902A1 (en) * 2000-04-05 2004-02-26 Pincus Matthew R. Peptides selectively lethal to malignant and transformed mammalian cells
US6989239B2 (en) * 2001-06-20 2006-01-24 R.E.D. Laboratories, N.V./S.A. Methods for diagnosis and treatment of chronic immune diseases
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
JP2005520866A (ja) * 2002-03-12 2005-07-14 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 哺乳動物の悪性細胞および形質転換細胞に対する選択的致死性ペプチド
US7534861B2 (en) * 2003-01-10 2009-05-19 Ambergen, Inc. Compositions and methods for immunoaffinity purification
JP4051327B2 (ja) * 2003-09-19 2008-02-20 新科實業有限公司 垂直磁気記録ヘッドおよびその製造方法、ならびに磁気記録装置
EP1680443B9 (de) * 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Peptide mit stabilisierter alpha-helix und deren verwendungen
WO2005074521A2 (en) * 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
WO2005097820A1 (en) * 2004-04-06 2005-10-20 Korea Research Institute Of Bioscience And Biotechnology Peptides for inhibiting mdm2 function
CA2564584A1 (en) * 2004-04-22 2005-12-01 Carsten Schubert Hdm2-inhibitor complexes and uses thereof
CN101636407B (zh) 2006-12-14 2015-08-26 爱勒让治疗公司 双巯基大环化***
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
ES2649941T3 (es) 2007-02-23 2018-01-16 Aileron Therapeutics, Inc. Aminoácidos sustituidos para preparar péptidos macrocíclicos unidos a triazol
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
EP2224961A1 (de) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen
US20090275519A1 (en) * 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US20110144303A1 (en) * 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
EP2310407A4 (de) * 2008-04-08 2011-09-14 Aileron Therapeutics Inc Biologisch wirksame peptidomimetische makrozyklen
WO2010011313A2 (en) * 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
KR101220516B1 (ko) * 2010-01-21 2013-01-10 연세대학교 산학협력단 항－ｍｄｍ２를 발현하는 인간 성체줄기세포 및 그의 용도
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
DK2920197T3 (da) 2012-09-26 2021-05-31 Harvard College Prolinlåste sammenhæftede peptider og anvendelser deraf
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
SG10201700952XA (en) 2013-03-13 2017-04-27 Harvard College Stapled and stitched polypeptides and uses thereof
US10227390B2 (en) 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US10533039B2 (en) 2014-05-21 2020-01-14 President And Fellows Of Harvard College Ras inhibitory peptides and uses thereof
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
MX2017003797A (es) * 2014-09-24 2017-06-15 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
KR101652894B1 (ko) * 2014-12-18 2016-09-02 가천대학교 산학협력단 대장암에 대한 신규 바이오마커 및 그의 용도
CN107614003A (zh) 2015-03-20 2018-01-19 艾瑞朗医疗公司 拟肽大环化合物及其用途
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9765117B2 (en) 2015-08-24 2017-09-19 Romek Figa Peptides for treating cancer
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US20210032364A1 (en) * 2017-07-27 2021-02-04 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
WO1994000601A1 (en) * 1992-06-26 1994-01-06 The Trustees Of Princeton University Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
CA2124595A1 (en) * 1992-09-30 1994-04-14 Hanswalter Zentgraf Process for detecting p53-specific antibodies
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
US5532348A (en) * 1993-07-30 1996-07-02 United States Of America E6 associated protein and methods of use thereof

Also Published As

Publication number Publication date
DE69533855D1 (de) 2005-01-20
US6153391A (en) 2000-11-28
CA2195533A1 (en) 1996-02-01
AU2987695A (en) 1996-02-16
NZ289899A (en) 2000-08-25
JP3961015B2 (ja) 2007-08-15
AU684194B2 (en) 1997-12-04
DE69533855T2 (de) 2005-12-08
JPH10506525A (ja) 1998-06-30
WO1996002642A1 (en) 1996-02-01
JP2007222170A (ja) 2007-09-06
US5770377A (en) 1998-06-23
EP0773996B1 (de) 2004-12-15
EP0773996A1 (de) 1997-05-21

Similar Documents

Publication Publication Date Title
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
HUP9904023A2 (hu) Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
DE69805973T2 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DK0942740T3 (da) Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
WO1998026747A3 (en) Superantigen based methods and compositions for treatment of diseases
DE69324487D1 (de) Rezeptorbindende region des diphtherietoxius
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
ATE342278T1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
DE69534325D1 (de) Peptide zur behandlung von krebs
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
DE69420229T2 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
DE69805305T2 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69408394D1 (de) 4-Piperidino-piperidin zur Behandlung von Tumoren
ATE224387T1 (de) N-(pyridinylamino)isoindoline und verwandte verbindungen
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0773996

Country of ref document: EP

REN Ceased due to non-payment of the annual fee